Csilla Rozsa
Overview
Explore the profile of Csilla Rozsa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
559
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rozsa C
Ideggyogy Sz
. 2025 Mar;
78(1-2):27-36.
PMID: 40042456
Myasthenia gravis (MG) is an antibody-mediated disorder of the neuromuscular transmission, presenting with fatigable weakness that is either isolated to ocular muscles only or generalised (limb, bulbar and respiratory muscles...
2.
Dhondt R, Dedja K, Aerts S, Van Wijmeersch B, Kalincik T, Reddel S, et al.
Comput Methods Programs Biomed
. 2025 Feb;
263:108624.
PMID: 39965473
Background: Prognostic machine learning research in multiple sclerosis has been mainly focusing on black-box models predicting whether a patients' disability will progress in a fixed number of years. However, as...
3.
Bril V, Berkowicz T, Szczudlik A, Nicolle M, Bednarik J, Hon P, et al.
Muscle Nerve
. 2024 Nov;
71(1):43-54.
PMID: 39506903
Introduction/aims: Prospective, randomized, controlled trials of intravenous immunoglobulin (IVIG) maintenance therapy in myasthenia gravis (MG) are lacking. In this trial, we evaluated the safety and efficacy of caprylate/chromatography-purified IVIG; (IGIV-C)...
4.
De Brouwer E, Becker T, Werthen-Brabants L, Dewulf P, Iliadis D, Dekeyser C, et al.
PLOS Digit Health
. 2024 Jul;
3(7):e0000533.
PMID: 39052668
Background: Disability progression is a key milestone in the disease evolution of people with multiple sclerosis (PwMS). Prediction models of the probability of disability progression have not yet reached the...
5.
Rajda C, Rozsa C, Mike A, Lovas G, Mezei Z, Jakab G, et al.
Orphanet J Rare Dis
. 2023 Jul;
18(1):183.
PMID: 37420270
Multiple sclerosis (MS) may impact quality of life, careers and family plans of the affected individuals. The current treatments with disease modifying therapies aim to prevent people with MS (pwMS)...
6.
Bril V, Szczudlik A, Vaitkus A, Rozsa C, Kostera-Pruszczyk A, Hon P, et al.
Neurology
. 2022 Oct;
100(7):e671-e682.
PMID: 36270895
Background And Objectives: Myasthenia gravis (MG) is an autoimmune disease characterized by dysfunction at the neuromuscular junction. Treatment frequently includes corticosteroids (CSs) and IV immunoglobulin (IVIG). This study was conducted...
7.
Kas J, Bogyo L, Feher C, Ghimessy A, Gieszer B, Karsko L, et al.
Magy Seb
. 2022 Jul;
75(2):79-95.
PMID: 35895535
Introduction. Thymoma is the most common tumour of the anterior mediastinum. Video-Assisted Thoracic Surgery technique of thymoma resection is spreading world-wide, but the thoracoscopic method is still contentious in many...
8.
Sharmin S, Bovis F, Malpas C, Horakova D, Kubala Havrdova E, Izquierdo G, et al.
Eur J Neurol
. 2022 May;
29(8):2321-2334.
PMID: 35582938
Background And Purpose: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on...
9.
Biernacki T, Sandi D, Fuvesi J, Fricska-Nagy Z, Kincses T, Acs P, et al.
PLoS One
. 2022 Apr;
17(4):e0267346.
PMID: 35452476
Background: Fingolimod was approved and reimbursed by the healthcare provider in Hungary for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS) in 2012. The present study aimed to assess...
10.
Spelman T, Herring W, Zhang Y, Tempest M, Pearson I, Freudensprung U, et al.
Pharmacoeconomics
. 2021 Dec;
40(3):323-339.
PMID: 34921350
Background: Patients with highly active relapsing-remitting multiple sclerosis inadequately responding to first-line therapies (interferon-based therapies, glatiramer acetate, dimethyl fumarate, and teriflunomide, known collectively as "BRACETD") often switch to natalizumab or...